
Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.
Edwin M. Posadas, MD, FACP, discusses the results of a phase Ib study that looked at abiraterone and docetaxel for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Edwin M. Posadas, MD, FACP, medical director, Urologic Oncology Program, Cedars-Sinai’s Samuel Oschin Comprehensive Cancer Institute, discusses the results of a phase Ib study that looked at abiraterone and docetaxel for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
More about this study > >






